Advancements in antibody-drug conjugates as cancer therapeutics
Antibody-drug conjugates (ADCs) represent a promising approach in targeted cancer therapy, combining the targeted precision of antibodies with the potency of cytotoxic payloads to selectively target tumour cell whilst minimising off-target effects. This review provides a comprehensive analysis of AD...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | Journal of the National Cancer Center |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667005425000432 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849706212266868736 |
|---|---|
| author | Jung Yin Fong Zhixin Phuna Di Yang Chong Christophorus Manuel Heryanto Yu Shyan Low Khang Chiang Oh Yan Huen Lee Allan Wee Ren Ng Lionel Lian Aun In Michelle Yee Mun Teo |
| author_facet | Jung Yin Fong Zhixin Phuna Di Yang Chong Christophorus Manuel Heryanto Yu Shyan Low Khang Chiang Oh Yan Huen Lee Allan Wee Ren Ng Lionel Lian Aun In Michelle Yee Mun Teo |
| author_sort | Jung Yin Fong |
| collection | DOAJ |
| description | Antibody-drug conjugates (ADCs) represent a promising approach in targeted cancer therapy, combining the targeted precision of antibodies with the potency of cytotoxic payloads to selectively target tumour cell whilst minimising off-target effects. This review provides a comprehensive analysis of ADCs, encompassing their structural components, mechanisms of action, and clinical applications. It also examines recent technological advancements, particularly in antibody engineering and linker design, aimed at enhancing therapeutic efficacy and safety. The current clinical landscape is outlined, highlighting approved ADCs and promising candidates in clinical trials, while also addressing key challenges such as stability, half-life, and systemic toxicity. This review is based on an extensive literature survey from major databases such as Scopus and Web of Science, with a focus on keywords like “antibody-drug conjugates”, “ADC advancements”, and “next-generation ADC technologies”. By integrating insights from both preclinical and clinical perspectives, we highlight the transformative potential of ADCs in advancing modern cancer therapy. |
| format | Article |
| id | doaj-art-2a7053946e92470eaa3e8d23ae7f6930 |
| institution | DOAJ |
| issn | 2667-0054 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of the National Cancer Center |
| spelling | doaj-art-2a7053946e92470eaa3e8d23ae7f69302025-08-20T03:16:15ZengElsevierJournal of the National Cancer Center2667-00542025-08-015436237810.1016/j.jncc.2025.01.007Advancements in antibody-drug conjugates as cancer therapeuticsJung Yin Fong0Zhixin Phuna1Di Yang Chong2Christophorus Manuel Heryanto3Yu Shyan Low4Khang Chiang Oh5Yan Huen Lee6Allan Wee Ren Ng7Lionel Lian Aun In8Michelle Yee Mun Teo9Department of Biotechnology, Faculty of Applied Sciences, UCSI University, Kuala Lumpur, Malaysia; Cancer Immunotherapy Research Group (CIRG), Faculty of Applied Sciences, UCSI University, Kuala Lumpur, MalaysiaSchool of Medicine, Faculty of Health and Medical Sciences, Taylor’s University, Selangor, Malaysia; Faculty of Medicine and Health Sciences, School of Healthy Aging, Aesthetics and Regenerative Medicine, UCSI University, Kuala Lumpur, MalaysiaDepartment of Biotechnology, Faculty of Applied Sciences, UCSI University, Kuala Lumpur, Malaysia; Cancer Immunotherapy Research Group (CIRG), Faculty of Applied Sciences, UCSI University, Kuala Lumpur, MalaysiaDepartment of Biotechnology, Faculty of Applied Sciences, UCSI University, Kuala Lumpur, Malaysia; Cancer Immunotherapy Research Group (CIRG), Faculty of Applied Sciences, UCSI University, Kuala Lumpur, MalaysiaDepartment of Biotechnology, Faculty of Applied Sciences, UCSI University, Kuala Lumpur, Malaysia; Cancer Immunotherapy Research Group (CIRG), Faculty of Applied Sciences, UCSI University, Kuala Lumpur, MalaysiaDepartment of Biotechnology, Faculty of Applied Sciences, UCSI University, Kuala Lumpur, Malaysia; Cancer Immunotherapy Research Group (CIRG), Faculty of Applied Sciences, UCSI University, Kuala Lumpur, MalaysiaDepartment of Biotechnology, Faculty of Applied Sciences, UCSI University, Kuala Lumpur, MalaysiaCancer Immunotherapy Research Group (CIRG), Faculty of Applied Sciences, UCSI University, Kuala Lumpur, Malaysia; School of Chemistry, Chemical Engineering and Biotechnology, Nanyang Technological University, SingaporeDepartment of Biotechnology, Faculty of Applied Sciences, UCSI University, Kuala Lumpur, Malaysia; Cancer Immunotherapy Research Group (CIRG), Faculty of Applied Sciences, UCSI University, Kuala Lumpur, MalaysiaDepartment of Biotechnology, Faculty of Applied Sciences, UCSI University, Kuala Lumpur, Malaysia; Cancer Immunotherapy Research Group (CIRG), Faculty of Applied Sciences, UCSI University, Kuala Lumpur, Malaysia; Corresponding author.Antibody-drug conjugates (ADCs) represent a promising approach in targeted cancer therapy, combining the targeted precision of antibodies with the potency of cytotoxic payloads to selectively target tumour cell whilst minimising off-target effects. This review provides a comprehensive analysis of ADCs, encompassing their structural components, mechanisms of action, and clinical applications. It also examines recent technological advancements, particularly in antibody engineering and linker design, aimed at enhancing therapeutic efficacy and safety. The current clinical landscape is outlined, highlighting approved ADCs and promising candidates in clinical trials, while also addressing key challenges such as stability, half-life, and systemic toxicity. This review is based on an extensive literature survey from major databases such as Scopus and Web of Science, with a focus on keywords like “antibody-drug conjugates”, “ADC advancements”, and “next-generation ADC technologies”. By integrating insights from both preclinical and clinical perspectives, we highlight the transformative potential of ADCs in advancing modern cancer therapy.http://www.sciencedirect.com/science/article/pii/S2667005425000432Antibody-drug conjugatesCancerTargeted therapyAntibodyLinker |
| spellingShingle | Jung Yin Fong Zhixin Phuna Di Yang Chong Christophorus Manuel Heryanto Yu Shyan Low Khang Chiang Oh Yan Huen Lee Allan Wee Ren Ng Lionel Lian Aun In Michelle Yee Mun Teo Advancements in antibody-drug conjugates as cancer therapeutics Journal of the National Cancer Center Antibody-drug conjugates Cancer Targeted therapy Antibody Linker |
| title | Advancements in antibody-drug conjugates as cancer therapeutics |
| title_full | Advancements in antibody-drug conjugates as cancer therapeutics |
| title_fullStr | Advancements in antibody-drug conjugates as cancer therapeutics |
| title_full_unstemmed | Advancements in antibody-drug conjugates as cancer therapeutics |
| title_short | Advancements in antibody-drug conjugates as cancer therapeutics |
| title_sort | advancements in antibody drug conjugates as cancer therapeutics |
| topic | Antibody-drug conjugates Cancer Targeted therapy Antibody Linker |
| url | http://www.sciencedirect.com/science/article/pii/S2667005425000432 |
| work_keys_str_mv | AT jungyinfong advancementsinantibodydrugconjugatesascancertherapeutics AT zhixinphuna advancementsinantibodydrugconjugatesascancertherapeutics AT diyangchong advancementsinantibodydrugconjugatesascancertherapeutics AT christophorusmanuelheryanto advancementsinantibodydrugconjugatesascancertherapeutics AT yushyanlow advancementsinantibodydrugconjugatesascancertherapeutics AT khangchiangoh advancementsinantibodydrugconjugatesascancertherapeutics AT yanhuenlee advancementsinantibodydrugconjugatesascancertherapeutics AT allanweerenng advancementsinantibodydrugconjugatesascancertherapeutics AT lionellianaunin advancementsinantibodydrugconjugatesascancertherapeutics AT michelleyeemunteo advancementsinantibodydrugconjugatesascancertherapeutics |